Matthew Geriak
Impact in
- Infectious Diseases top 5%
- Antimicrobial Resistance in Staphylococcus
- COVID-19 Clinical Research Studies
- Clinical Biochemistry top 5%
- Bacterial Identification and Susceptibility Testing
Papers in
-
- Antimicrobial Resistance in Staphylococcus 8
- COVID-19 Clinical Research Studies 3
-
- Bacterial Identification and Susceptibility Testing 5
- Co-authors
- George Sakoulas (16 shared papers)Victor Nizet (8 shared papers)Ravina Kullar (6 shared papers)Fadi Haddad (5 shared papers)Warren E. Rose (5 shared papers)Marcus Zervos (3 shared papers)Kerry L. LaPlante (1 shared paper)Erlinda R. Ulloa (2 shared papers)
- Journals
- Clinical Infectious Diseases (3 papers)Open Forum Infectious Diseases (3 papers)Frontiers in Immunology (2 papers)Infectious Diseases and Therapy (2 papers)mSphere (1 paper)
- Partner nations
- United StatesAustralia
In The Last Decade
Matthew Geriak
19 papers receiving 469 citations
Peers
Comparison fields: 5 of 58
- Infectious Diseases 297
- Clinical Biochemistry 102
- Applied Microbiology and Biotechnology 18
- Molecular Medicine 39
- Pharmacology 77
Countries citing papers authored by Matthew Geriak
This map shows the geographic impact of Matthew Geriak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Geriak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Geriak more than expected).
Fields of papers citing papers by Matthew Geriak
This network shows the impact of papers produced by Matthew Geriak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Geriak. The network helps show where Matthew Geriak may publish in the future.
Co-authors
The 25 scholars most cited alongside Matthew Geriak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 147 | |
| 2 | 2019 | 66 | |
| 3 | 2021 | 48 | |
| 4 | 2020 | 35 | |
| 5 | 2019 | 34 | |
| 6 | 2018 | 31 | |
| 7 | 2014 | 23 | |
| 8 | 2020 | 22 | |
| 9 | 2021 | 22 | |
| 10 | 2021 | 12 | |
| 11 | 2023 | 10 | |
| 12 | 2022 | 8 | |
| 13 | 2022 | 6 | |
| 14 | 2009 | 4 | |
| 15 | 2022 | 3 | |
| 16 | 2025 | 1 | |
| 17 | 2023 | 1 | |
| 18 | 2025 | 1 | |
| 19 | Multicenter Cohort of Patients With Methicillin-Resistant | 2020 | 1 |
About Matthew Geriak
Matthew Geriak is a scholar working on Infectious Diseases, Clinical Biochemistry, Pharmacology, Epidemiology and Pediatrics, Perinatology and Child Health, having authored 19 papers that have together received 475 indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (8 papers), Bacterial Identification and Susceptibility Testing (5 papers), COVID-19 Clinical Research Studies (3 papers), Infective Endocarditis Diagnosis and Management (2 papers), Drug-Induced Adverse Reactions (2 papers), Antibiotics Pharmacokinetics and Efficacy (2 papers), Pharmaceutical Practices and Patient Outcomes (1 paper) and Contact Dermatitis and Allergies (1 paper). The work is most often cited by research in Infectious Diseases (297 citations), Clinical Biochemistry (102 citations), Applied Microbiology and Biotechnology (18 citations), Molecular Medicine (39 citations) and Pharmacology (77 citations). Matthew Geriak has collaborated with scholars based in United States and Australia. Frequent co-authors include George Sakoulas, Victor Nizet, Ravina Kullar, Fadi Haddad, Warren E. Rose, Marcus Zervos, Kerry L. LaPlante, Erlinda R. Ulloa, Kavindra V. Singh and Barbara E. Murray. Their work appears in journals such as Clinical Infectious Diseases, Open Forum Infectious Diseases, Frontiers in Immunology, Infectious Diseases and Therapy and mSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.